JP Morgan Maintains Neutral on Haemonetics, Lowers Price Target to $62

Benzinga Newsdesk www.benzinga.com Negative 70.9%

Neg 70.9% Neu 0% Pos 0%

JP Morgan analyst Allen Gong maintains Haemonetics (NYSE:HAE) with a Neutral and lowers the price target from $74 to $62.